NEUROCRINE BIOSCIENCES INC (NBIX) Stock Price & Overview
NASDAQ:NBIX • US64125C1099
The current stock price of NBIX is 129.54 USD. Today NBIX is down by -0.25%. In the past month the price decreased by -5.89%. In the past year, price increased by 16.97%.
NBIX Key Statistics
- Market Cap
- 13.001B
- P/E
- 27.80
- Fwd P/E
- 21.20
- EPS (TTM)
- 4.66
- Dividend Yield
- N/A
NBIX Stock Performance
NBIX Stock Chart
NBIX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NBIX. When comparing the yearly performance of all stocks, NBIX turns out to be only a medium performer in the overall market: it outperformed 44.32% of all stocks.
NBIX Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NBIX. NBIX gets an excellent profitability rating and is at the same time showing great financial health properties.
NBIX Earnings
On February 11, 2026 NBIX reported an EPS of 1.48 and a revenue of 805.50M. The company missed EPS expectations (-22.89% surprise) and missed revenue expectations (-0.28% surprise).
NBIX Forecast & Estimates
36 analysts have analysed NBIX and the average price target is 179.61 USD. This implies a price increase of 38.65% is expected in the next year compared to the current price of 129.54.
For the next year, analysts expect an EPS growth of 31.12% and a revenue growth 21.05% for NBIX
NBIX Groups
Sector & Classification
NBIX Financial Highlights
Over the last trailing twelve months NBIX reported a non-GAAP Earnings per Share(EPS) of 4.66. The EPS increased by 41.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.73% | ||
| ROA | 10.33% | ||
| ROE | 14.71% | ||
| Debt/Equity | 0 |
NBIX Ownership
NBIX Latest News, Press Relases and Analysis
NBIX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.34 | 402.577B | ||
| AMGN | AMGEN INC | 16.55 | 203.574B | ||
| GILD | GILEAD SCIENCES INC | 16.52 | 181.247B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.4 | 125.079B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.57 | 81.897B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.95 | 42.495B | ||
| INSM | INSMED INC | N/A | 30.048B | ||
| BIIB | BIOGEN INC | 11.85 | 27.955B | ||
| NTRA | NATERA INC | N/A | 27.865B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.24 | 23.875B | ||
| MRNA | MODERNA INC | N/A | 22.105B | ||
| EXAS | EXACT SCIENCES CORP | 340.18 | 19.738B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.736B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NBIX
Company Profile
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 2,000 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Company Info
IPO: 1996-05-23
NEUROCRINE BIOSCIENCES INC
6027 Edgewood Bend Court
San Diego CALIFORNIA 92130 US
CEO: Kevin C. Gorman
Employees: 2000
Phone: 18586177600
NEUROCRINE BIOSCIENCES INC / NBIX FAQ
What does NBIX do?
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 2,000 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
What is the current price of NBIX stock?
The current stock price of NBIX is 129.54 USD. The price decreased by -0.25% in the last trading session.
Does NBIX stock pay dividends?
NBIX does not pay a dividend.
What is the ChartMill rating of NEUROCRINE BIOSCIENCES INC stock?
NBIX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Can you provide the number of employees for NEUROCRINE BIOSCIENCES INC?
NEUROCRINE BIOSCIENCES INC (NBIX) currently has 2000 employees.
What is NEUROCRINE BIOSCIENCES INC worth?
NEUROCRINE BIOSCIENCES INC (NBIX) has a market capitalization of 13.00B USD. This makes NBIX a Large Cap stock.
Who owns NEUROCRINE BIOSCIENCES INC?
You can find the ownership structure of NEUROCRINE BIOSCIENCES INC (NBIX) on the Ownership tab.